Genetics Institute, Inc.

Wyeth

Philogen S.p.a.

Denise M O'Hara

Geertruida Machteld Veldman

Mary Collins

Gary S Gray

Beatriz M Carreno

Maximiliano Vasquez

Samuel Goldman

Man Sung Co

Abbie Cheryl Celniker

Andrea Knight

Bonita Rup

Neil M Wolfman

Monique V Davies

Kristie Grove Bridges

Lisa-Anne Whittemore

Tejvir S Khurana

Jane Aghajanian

Mary L Bouxsein

William J Dunham, Legal Representative

Naoya Tsurushita

Clive R Wood

Paul Robert Hinton

Katherine Jane Turner

Kathrin Schwager

Giovanni Neri

Jianqing Chen

Melanie C Ruzek

Donna Morris

Specific binding members that bind the ED-A isoform of fibronectin for use in methods of treatment, diagnosis, detection and/or imaging of inflammatory bowel disease (IBD), and/or for use in delivery to the IBD tissue of a molecule conjugated to the specific binding member. The specific binding member may, for example, be conjugated to an immunosupressive or anti-inflammatory molecule, such as interleukin-10.

Anti-ED-A immunoconjugates for inflammatory bowel disease

The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.

Isolated cell comprising a nucleic acid encoding antibody inhibitors of gdf-8 and uses thereof

Isolated nucleic acid molecule encoding an antibody that reduces GDF-8 activity

Method of increasing trabecular bone density in a patient in need thereof by an antibody against GDF-8

Methods of increasing muscle mass or muscle strength using antibody inhibitors of GDF-8

The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

Methods of treatment of autoimmune diseases using humanized immunoglobulin reactive with B7-2

The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules

Antibody inhibitors of GDF-8 and uses thereof

The invention provides an antibody-toxic moiety conjugates comprising an antibody that specifically recognizes a molecule expressed on the surface of a T cell which is expressed only on T cells and is only expressed transiently on T cells upon T cell activation. Preferably, the T cell molecule is CTLA4. The invention further provides anti-CTLA4 antibodies and humanized forms thereof.

Antibodies against CTLA4

Method of transplanting cells by contacting donor cells with B7-1-and B7-2-specific immunoglobulins

Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith

Humanized immunoglobulin reactive with B7 therewith

Humanized immunoglobulin reactive with b7-2 and methods of treatment therewith

Growing community of inventors

Reading, MA, United States of America

Denise M O'Hara